![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0014.png)
Page 46
Notes:
conferenceseries
.com
Volume 8
Journal of Clinical & Experimental Pharmacology
Pharmacology and Medicinal Chemistry 2018
October 18-19, 2018
October 18-19, 2018 Dubai, UAE
International Conference on
18
th
International Conference on
&
Joint Meeting on
Pharmacology and Toxicology
Medicinal and Pharmaceutical Chemistry
Evaluation of ayurvedic formulation against chemical induced chronic pancreatitis in rats
Chaitra Harsha, Pradeep, Kumaraswamay and Sasikumar
Vipragen Bioscience Private Limited, Mysore
C
hronic pancreatitis is characterized by inflammation, fibrosis, and loss of exocrine (acinar cells) and endocrine (islets)
tissue. In this study, L-arginine induced chronic pancreatitis model has been developed and the effect of Amar, an
ayurvedic formulation on the chronic pancreatitis was studied in male Wistar rats. Animals were treated with vehicle control,
Amar (25, 50 and 100 mg/kg/day) and methylprednisolone for a maximum period of 21 days and observed for general clinical
parameters, clinical pathology parameters, anti-oxidant levels, inflammatory cytokines and pathological changes. oral (gavage)
administration of Amar upto 100 mg/kg/day ameliorated the L-arginine induced changes in Chronic pancreatitis model in
male Wistar rats. The treatment of Amar reduced the oxidative stress, the level of inflammatory cytokines levels and structural
changes in pancreas. The results showed that antioxidant and anti-inflammatory properties of Amar could be the possible
reason for its amelioration effect in L-arginine induced chronic pancreatitis model in male Wistar rats.
Biography
Chaitra Harsha is a Medical Doctor with PhD from Indian Institute of Science, India. She has also received Management degree from Indian Institute of Management,
Bangalore, India. She is the Managing Director of Vipragen since 2015 and heads a team of 38 highly skilled scientific personnel.
chaitra.harsha@vipragen.comChaitra Harsha
et.al., Clin Exp Pharmacol 2018, Volume 8
DOI: 10.4172/2161-1459-C3-034